Live or let die: the cell's response to p53 - PubMed (original) (raw)

Review

doi: 10.1038/nrc864.

Affiliations

• PMID: 12154352
• DOI: 10.1038/nrc864

Review

Live or let die: the cell's response to p53

Karen H Vousden et al. Nat Rev Cancer. 2002 Aug.

No abstract available

PubMed Disclaimer

Similar articles

• Inactivation of Myc-induced p53-dependent apoptosis in human tumors.
  Henriksson M, Selivanova G, Lindström M, Wiman KG. Henriksson M, et al. Apoptosis. 2001 Feb-Apr;6(1-2):133-7. doi: 10.1023/a:1009644716727. Apoptosis. 2001. PMID: 11321036 Review.
• To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
  Workman P. Workman P. Hum Exp Toxicol. 1995 Feb;14(2):222-5. doi: 10.1177/096032719501400213. Hum Exp Toxicol. 1995. PMID: 7779451 Review. No abstract available.
• The p53 homology trap.
  Knight RA, Candi E, Melino G. Knight RA, et al. Cancer Biol Ther. 2003 Jan-Feb;2(1):63-6. doi: 10.4161/cbt.192. Cancer Biol Ther. 2003. PMID: 12673119 No abstract available.
• [Rescue of nonsense mutated p53 by readthrough leads to apoptosis in cancers cells].
  Floquet C, Rousset JP, Bidou L. Floquet C, et al. Med Sci (Paris). 2011 Jun-Jul;27(6-7):585-6. doi: 10.1051/medsci/2011276008. Epub 2011 Jul 1. Med Sci (Paris). 2011. PMID: 21718640 French. No abstract available.
• [p53 mutations and their role in tumorigenesis].
  Tsuchida N, Munirajan AK. Tsuchida N, et al. Tanpakushitsu Kakusan Koso. 1997 Jul;42(10 Suppl):1567-75. Tanpakushitsu Kakusan Koso. 1997. PMID: 9279083 Review. Japanese. No abstract available.

Cited by

• PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA.
  Jana S, Mondal M, Mahale S, Gupta B, Prasasvi KR, Kandasami L, Jha N, Chowdhury A, Santosh V, Kanduri C, Somasundaram K. Jana S, et al. Elife. 2024 Sep 20;12:RP88256. doi: 10.7554/eLife.88256. Elife. 2024. PMID: 39302097 Free PMC article.
• BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.
  Pervushin NV, Nilov DK, Pushkarev SV, Shipunova VO, Badlaeva AS, Yapryntseva MA, Kopytova DV, Zhivotovsky B, Kopeina GS. Pervushin NV, et al. Apoptosis. 2024 Dec;29(11-12):2197-2213. doi: 10.1007/s10495-024-02014-8. Epub 2024 Sep 2. Apoptosis. 2024. PMID: 39222276 Free PMC article.
• Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions.
  Li T, Liu X, Qian H, Zhang S, Hou Y, Zhang Y, Luo G, Zhu X, Tao Y, Fan M, Wang H, Sha C, Lin A, Qin J, Gu K, Chen W, Fu T, Wang Y, Wei Y, Wu Q, Tan W. Li T, et al. Nat Commun. 2024 Aug 8;15(1):6751. doi: 10.1038/s41467-024-51197-w. Nat Commun. 2024. PMID: 39117705 Free PMC article.
• The role of clonal progression leading to the development of therapy-related myeloid neoplasms.
  Guarnera L, Pascale MR, Hajrullaj H, Cristiano A, Mallegni F, Onorato A, Voso MT, Fabiani E. Guarnera L, et al. Ann Hematol. 2024 Sep;103(9):3507-3517. doi: 10.1007/s00277-024-05803-y. Epub 2024 Jul 20. Ann Hematol. 2024. PMID: 39031199 Free PMC article.
• CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status.
  Zhang H, Zheng T, Qin C, Zhang X, Lin H, Huang X, Liu Q, Chang S, Zhang L, Guo J, Zhang Y, Bian C, Liu H. Zhang H, et al. Cancer Gene Ther. 2024 Aug;31(8):1151-1163. doi: 10.1038/s41417-024-00806-3. Epub 2024 Jul 13. Cancer Gene Ther. 2024. PMID: 38997438

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal